Cell therapy for type 1 diabetes: from islet transplantation to stem cells

Background. The field of cell therapy of type 1 diabetes is a particularly interesting example in the scenario of regenerative medicine. In fact, beta cell replacement has its roots in the experience of islet transplantation, which began 40 years ago, and is currently a rapidly accelerating field, with several ongoing clinical trials using beta cells derived from stem cells. Summary. Type 1 diabetes is particularly suitable for cell therapy as it is a disease due to the deficiency of only one cell type, the insulin-producing beta cell, and this endocrine cell does not need to be positioned inside the pancreas to perform its function. On the other hand, the presence of a double immunological barrier, the allogeneic one and the autoimmune one, make the protection of beta cells from rejection a major challenge. Until today, islet transplantation has taught us a lot, pioneering immunosuppressive therapies, graft encapsulation, tissue engineering, test of different implant sites and has stimulated a great variety of studies on beta cell function. Nowadays, it is indeed possible to generate functional beta cells from the differentiation of pluripotent stem cells and the first pioneering clinical trials with these cells are ongoing. This review starts from islet transplantation, presenting its current indications and the latest published trials to arrive at the prospects of stem cell therapy, presenting the latest innovations in the field.Key messages. The field of beta cell replacement is moving forward quickly, especially thanks to all the knowledge generated by the experience of islet transplantation.

Automated summary

Cell therapy for type 1 diabetes is an important field in regenerative medicine, with ongoing clinical trials using beta cells derived from stem cells. The experience of islet transplantation has provided valuable knowledge and advancements for beta cell replacement therapy.